Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.
Inflammation is an important contributor to lung tumor development and progression. In addition, inflammatory signaling may promote epithelial to mesenchymal transition, development of aggressive metastatic tumor phenotypes, and play a role in resistance to targeted therapies. New insights in inflammatory signaling have led to the evaluation of combination therapies that target these specific pathways. In addition to developing the optimal combination of targeted agents, biomarker-based selection of patients who will likely benefit will be critical to the success of this strategy. Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Krysan
Kostyantyn
K
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. KKrysan@mednet.ucla.edu
Lee
Jay M
JM
Dohadwala
Mariam
M
Gardner
Brian K
BK
Reckamp
Karen L
KL
Garon
Edward
E
St John
Maie
M
Sharma
Sherven
S
Dubinett
Steven M
SM
D014408:Biomarkers, Tumor / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology; D002471:Cell Transformation, Neoplastic; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D020935:MAP Kinase Signaling System / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism
D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D043562:Receptors, G-Protein-Coupled; D051546:Cyclooxygenase 2; D066246:ErbB Receptors; D015232:Dinoprostone